Results from a small, independently funded, double-blind, active-comparator trial suggest that baricitinib could be beneficial in the treatment of lupus nephritis. EULAR2023
for systemic lupus erythematosus. The trial results presented at EULAR suggest that baricitinib could be beneficial in the treatment of lupus nephritis, further establishing the role of JAK inhibitors in autoimmune disease therapy."Lupus nephritis typically develops within 5 years of initial lupus symptoms," said Hassanien, of the Rheumatology Research and Advanced Therapeutics Department at Assiut University, Assiut, Egypt.
The study’s primary endpoint of 24-hour proteinuria response rate at week 12 was significantly greater with baricitinib 4 mg daily, compared with monthly cyclophosphamide infusions at 0.7 mg/m in the baricitinib group and one patient in the cyclophosphamide group were affected. The researchers recorded no major adverse cardiovascular or venous thromboembolic events, which are known to occur at higher rates among some users of baricitinib and other JAK inhibitors.
"The primary endpoint is limited at proteinuria, while biopsy is considered the gold standard for measuring efficacy," said Eric F. Morand, MD, head of the Monash Health Rheumatology Unit, Melbourne, Australia. This was not the only critical comment regarding the study that emerged during the discussion. The use of a 4-mg dosage regimen throughout the entire study duration and the positive outcomes observed in the control group treated with cyclophosphamide were also mentioned.
Hassanien acknowledged that this is a small and relatively short study and disclosed plans to extend the follow-up period to 1 year and conduct a renal biopsy.European Alliance of Associations for Rheumatology 2023 Annual Meeting:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Promising Telitacicept Results Reported for Lupus, Sjögren'sResults of a phase 3 trial in Chinese patients with systemic lupus erythematosus showed a significantly greater response rate with telitacicept, compared with placebo.
Read more »
Box Office Results: Spider-Man: Across the Spider-Verse Spins a Mighty WebAfter nearly a dozen films, Spider-Man continues to slay at the box office as the results are in for Across the Spider-Verse.
Read more »
Lucid Air GT Takes On BMW M8 Competition In U-Drag Race With Surprising Results | CarscoopsPlace your bets on whether twin turbo V8 speed or over 800 electric ponies will take the checkered flag car auto cars
Read more »
Indian shares set to open higher on hopes of Fed rate hike pauseIndian shares will likely open higher on Monday, tracking gains in the broader Asian market, as mixed U.S. jobs data bolstered expectations that the Federal Reserve may skip an interest rate hike later this month.
Read more »